Gram-Negative Bacteria Bloodstream Infections in Patients with Hematological Malignancies – The Impact of Pathogen Type and Patterns of Antibiotic Resistance: A Retrospective Cohort Study

References

• ChenCY, TsayW, TangJL, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect. 2010;138(7):1044–1051.19941686
   PubMed Web of Science ®Google Scholar
• GudiolC, BodroM, SimonettiA, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013;19(5):474–479. doi:10.1111/j.1469-0691.2012.03879.x22524597
   PubMed Web of Science ®Google Scholar
• TrecarichiEM, PaganoL, CandoniA, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect. 2015;21(4):337–343. doi:10.1016/j.cmi.2014.11.02225595706
   PubMed Web of Science ®Google Scholar
• ZhuJ, ZhouK, JiangY, et al. Bacterial pathogens differed between neutropenic and non-neutropenic patients in the same hematological ward: an 8-year survey. Clin Infect Dis. 2018;67(suppl_2):S174–S178. doi:10.1093/cid/ciy64330423039
   PubMed Web of Science ®Google Scholar
• ScheichS, WeberS, ReinheimerC, et al. Bloodstream infections with gram-negative organisms and the impact of multidrug resistance in patients with hematological malignancies. Ann Hematol. 2018;97(11):2225–2234.29974230
   PubMed Web of Science ®Google Scholar
• AverbuchD, OraschC, CordonnierC, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica. 2013;98(12):1826–1835. doi:10.3324/haematol.2013.09102524323983
   PubMed Web of Science ®Google Scholar
• MertD, CekenS, IskenderG, et al. Epidemiology and mortality in bacterial bloodstream infections in patients with hematologic malignancies. J Infect Dev Ctries. 2019;13(8):727–735. doi:10.3855/jidc.1145732069257
   PubMed Web of Science ®Google Scholar
• RuhnkeM, ArnoldR, GastmeierP. Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol. 2014;15(13):e606–e619. doi:10.1016/S1470-2045(14)70344-425456379
   PubMed Web of Science ®Google Scholar
• MagiorakosAP, SrinivasanA, CareyRB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.21793988
   PubMed Web of Science ®Google Scholar
• SatlinMJ, WalshTJ. Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: three major threats to hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2017;19(6):e12762. doi:10.1111/tid.12762
   Web of Science ®Google Scholar
• GudiolC, CalatayudL, Garcia-VidalC, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65(2):333–341. doi:10.1093/jac/dkp41119959544
   PubMed Web of Science ®Google Scholar
• KangCI, ChungDR, KoKS, PeckKR, SongJH. Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol. 2012;91(1):115–121. doi:10.1007/s00277-011-1247-721556875
   PubMed Web of Science ®Google Scholar
• Cornejo-JuarezP, Vilar-CompteD, Perez-JimenezC, Namendys-SilvaSA, Sandoval-HernandezS, Volkow-FernandezP. The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. Int J Infect Dis. 2015;31:31–34. doi:10.1016/j.ijid.2014.12.02225528484
   PubMed Web of Science ®Google Scholar
• KimSH, KwonJC, ChoiSM, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome. Ann Hematol. 2013;92(4):533–541. doi:10.1007/s00277-012-1631-y23161391
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hematology CM, Chinese Medical Doctor Association. [Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2016)]. Zhonghua Xue Ye Xue Za Zhi. 2016;37(5):353–359. [ Chinese]27210867
   PubMedGoogle Scholar
• GengaKR, RussellJA. Update of sepsis in the intensive care unit. J Innate Immun. 2017;9(5):441–455. doi:10.1159/00047741928697503
   PubMed Web of Science ®Google Scholar
• GhafurA, DevarajanV, RajaT, et al. Monotherapy versus combination therapy against nonbacteremic carbapenem-resistant gram-negative infections: a retrospective observational study. Indian J Crit Care Med. 2017;21(12):825–829. doi:10.4103/ijccm.IJCCM_243_1729307962
   PubMedGoogle Scholar
• TammaPD, GoodmanKE, HarrisAD, et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis. 2017;64(3):257–264. doi:10.1093/cid/ciw74128013264
   PubMed Web of Science ®Google Scholar
• TangY, WuX, ChengQ, LiX. Inappropriate initial antimicrobial therapy for hematological malignancies patients with gram-negative bloodstream infections. Infection. 2020;48(1):109–116. doi:10.1007/s15010-019-01370-x31677085
   PubMed Web of Science ®Google Scholar
• TangY, ChengQ, YangQ, et al. Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections. Infection. 2018;46(4):513–521. doi:10.1007/s15010-018-1151-329767394
   PubMed Web of Science ®Google Scholar
• ZilberbergMD, ShorrAF, MicekST, Vazquez-GuillametC, KollefMH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014;18(6):596. doi:10.1186/s13054-014-0596-825412897
   PubMed Web of Science ®Google Scholar
• MarinM, GudiolC, ArdanuyC, et al. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. J Infect. 2014;69(5):417–423. doi:10.1016/j.jinf.2014.05.01824960295
   PubMed Web of Science ®Google Scholar
• ZhaiW, ZhangX, WeiJ, et al. A prospective observational study of antibiotic therapy in febrile neutropenia patients with hematological malignances from multiple centers in Northeast China. Int J Infect Dis. 2015;37:97–103. doi:10.1016/j.ijid.2015.04.01525931196
   PubMed Web of Science ®Google Scholar
• PaganoL, CairaM, TrecarichiEM, et al. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis. 2014;20(7):1235–1236. doi:10.3201/eid2007.13009424960464
   PubMed Web of Science ®Google Scholar
• HuF, ZhuD, WangF, WangM. Current status and trends of antibacterial resistance in China. Clin Infect Dis. 2018;67(suppl_2):S128–34. doi:10.1093/cid/ciy65730423045
   PubMed Web of Science ®Google Scholar
• LiuJ, WangH, HuangZ, et al. Risk factors and outcomes for carbapenem-resistant Klebsiella pneumoniae bacteremia in onco-hematological patients. J Infect Dev Ctries. 2019;13(5):357–364. doi:10.3855/jidc.1118932053504
   PubMed Web of Science ®Google Scholar
• Al-AnaziKA, Al-JasserAM. Infections caused by Acinetobacter baumannii in recipients of hematopoietic stem cell transplantation. Front Oncol. 2014;4:186.25072028
   PubMedGoogle Scholar
• TrecarichiEM, TumbarelloM, CairaM, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. 2011;96(1):e1–e3, e4. doi:10.3324/haematol.2010.03664021193424
   PubMed Web of Science ®Google Scholar
• HaYE, KangCI, ChaMK, et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. 2013;42(5):403–409. doi:10.1016/j.ijantimicag.2013.07.01824071027
   PubMed Web of Science ®Google Scholar
• LiangT, XuC, ChengQ, TangY, ZengH, LiX. Epidemiology, risk factors, and clinical outcomes of bloodstream infection due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in hematologic malignancy: a retrospective study from Central South China. Microb Drug Resist. 2020;27(6):800–80833232654
   PubMed Web of Science ®Google Scholar
• ZhangP, WangJ, HuH, et al. Clinical Characteristics and risk factors for bloodstream infection due to carbapenem-resistant Klebsiella pneumoniae in patients with hematologic malignancies. Infect Drug Resist. 2020;13:3233–3242. doi:10.2147/IDR.S27221733061470
   PubMed Web of Science ®Google Scholar
• SatlinMJ, CohenN, MaKC, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect. 2016;73(4):336–345. doi:10.1016/j.jinf.2016.07.00227404978
   PubMed Web of Science ®Google Scholar
• ZhangY, WangQ, YinY, et al. Epidemiology of carbapenem-resistant enterobacteriaceae infections: report from the China CRE network. Antimicrob Agents Chemother. 2018;62(2). doi:10.1128/AAC.01882-17.
   Web of Science ®Google Scholar
• ZhaoY, LinQ, LiuL, et al. Risk factors and outcomes of antibiotic-resistant pseudomonas aeruginosa bloodstream infection in adult patients with acute leukemia. Clin Infect Dis. 2020;71(Suppl 4):S386–S393. doi:10.1093/cid/ciaa152233367574
   PubMed Web of Science ®Google Scholar